CRNX - Crinetics Pharmaceuticals Inc
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
25%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -95.93%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -43191.05%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 22.53
Debt Ratio is 0.08
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Crinetics Pharmaceuticals Inc (CRNX) - https://www.crinetics.com/
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.Exchange - NASDAQ
Industry - Research and Development in Biotechnology
Sector - Professional, Scientific, and Technical Services
CEO - R. Scott Struthers
Employees - 194
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.